Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

Pharmacological inhibition of chromatin co-regulatory factors represents a clinically validated strategy to modulate oncogenic signaling through selective attenuation of gene expression. Here, we demonstrate that CBP/EP300 bromodomain inhibition preferentially abrogates the viability of multiple mye...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Andrew R Conery, Richard C Centore, Adrianne Neiss, Patricia J Keller, Shivangi Joshi, Kerry L Spillane, Peter Sandy, Charlie Hatton, Eneida Pardo, Laura Zawadzke, Archana Bommi-Reddy, Karen E Gascoigne, Barbara M Bryant, Jennifer A Mertz, Robert J Sims III
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	eLife Sciences Publications Ltd 2016-01-01
סדרה:	eLife
נושאים:	CBP EP300 bromodomain IRF4 MYC myeloma
גישה מקוונת:	https://elifesciences.org/articles/10483
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!